All In Biotech

Drug Trial Radar · NCT00508924

Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)

A Randomised, Open, Parallel-group, Multicentre Study to Examine the Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Combination With Clopidogrel and Aspirin in Patients Undergoing Elective Percutaneous Coronary Intervention in Comparison With Unfractionated Heparin, Clopidogrel and Aspirin

Last checked: Nov 20, 2026Latest source record: Jan 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 140 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

140

Actual

Start

Aug 2005

Primary completion

Not stated

Study completion Oct 2006

Sponsor

Lead sponsor
Tanabe Pharma CorporationIndustry
Sponsor type
Industry
First posted
Jul 30, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the information on dose-response of argatroban in pharmacodynamic markers and to assess the anticoagulation, safety and efficacy of argatroban in reference to unfractionated heparin, in combination with dual antiplatelet therapy.

Conditions

  • Coronary Artery Disease
  • Angina, Unstable

Interventions

  • ArgatrobanDrug

  • ArgatrobanDrug

  • ArgatrobanDrug

  • HeparinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Activated Clotting Time (ACT) Value After the First Dosing of Study Treatment.Time frame: 5 - 10 min after initial bolus
  2. Composite and Each of Death, Myocardial Infarction, and Urgent Revascularisation at Day 30, and Major Bleeding Events During Hospital Stay.Time frame: 30 Days

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Aalst, Belgium

  • Site not named

    Bad Nauheim, Germany

  • Site not named

    Cologne, Germany

  • Site not named

    Dachau, Germany

  • Site not named

    Düren, Germany

  • Site not named

    Frankfurt, Germany

  • Site not named

    Halle, Germany

  • Site not named

    Mainz, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.